NCT06633341View on ClinicalTrials.gov

Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 20, 2024

Primary Completion Date

October 20, 2027

Study Completion Date

October 20, 2027

Conditions
T-lymphoblastic Lymphoma
Interventions
BIOLOGICAL

CD5 CAR T-cells

Each subject receive CD5+ T-lymphoma Targeted CAR T-cells by intravenous infusion

Trial Locations (1)

310003

RECRUITING

The first affiliated hospital of medical college of zhejiang university, Hangzhou

All Listed Sponsors
collaborator

Yake Biotechnology Ltd.

INDUSTRY

lead

Zhejiang University

OTHER